Dr. Hellmann on the Design of the CheckMate-032 Study for Lung Cancer

Matthew D. Hellmann, MD
Published: Wednesday, Jul 12, 2017



Matthew D. Hellmann, MD, Memorial Sloan Kettering Cancer Center, discusses the design of the CheckMate-032 study investigating nivolumab (Opdivo) with or without ipilimumab (Yervoy) for patients with small cell lung cancer (SCLC).

There were 150 patients were assigned to receive either nivolumab or nivolumab plus ipilimumab in the nonrandomized cohort of the study, explains Hellmann.

The response rates of nivolumab plus ipilimumab was 23% compared with 11% with patients who receive nivolumab, states Hellmann.
 


Matthew D. Hellmann, MD, Memorial Sloan Kettering Cancer Center, discusses the design of the CheckMate-032 study investigating nivolumab (Opdivo) with or without ipilimumab (Yervoy) for patients with small cell lung cancer (SCLC).

There were 150 patients were assigned to receive either nivolumab or nivolumab plus ipilimumab in the nonrandomized cohort of the study, explains Hellmann.

The response rates of nivolumab plus ipilimumab was 23% compared with 11% with patients who receive nivolumab, states Hellmann.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x